Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Aveanna Healthcare Holdings ( (AVAH) ) has provided an update.
On November 13, 2025, Aveanna Healthcare Holdings Inc. amended its Stockholders Agreement, restricting certain executives from transferring common stock without pre-approval, while allowing other stockholders to transfer shares freely. Additionally, Christopher Gordon resigned as a Class II director, and Sam Weil, a Principal at Bain Capital, was appointed to fill the vacancy, bringing his expertise in healthcare investments to the board.
The most recent analyst rating on (AVAH) stock is a Hold with a $10.00 price target. To see the full list of analyst forecasts on Aveanna Healthcare Holdings stock, see the AVAH Stock Forecast page.
Spark’s Take on AVAH Stock
According to Spark, TipRanks’ AI Analyst, AVAH is a Neutral.
Aveanna Healthcare Holdings’ overall score is primarily influenced by its strong earnings call performance, indicating robust revenue and EBITDA growth. However, financial performance is constrained by high leverage and negative equity, and valuation concerns arise from a high P/E ratio. Technical indicators show a positive trend, but valuation remains a significant risk.
To see Spark’s full report on AVAH stock, click here.
More about Aveanna Healthcare Holdings
Aveanna Healthcare Holdings Inc. operates in the healthcare industry, focusing on healthcare delivery and life sciences. The company collaborates with private equity firms like Bain Capital and J.H. Whitney Capital Partners.
Average Trading Volume: 1,473,375
Technical Sentiment Signal: Buy
Current Market Cap: $1.84B
For an in-depth examination of AVAH stock, go to TipRanks’ Overview page.